Cosentyx Approved for Psoriasis
The U.S. FDA approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosentyx is manufactured by Novartis. The recommended dosing for Cosentyx is 300mg by subcutaneous injection administered in weeks 0, 1, 2, 3 and 4 followed by 300mg every 4 weeks. For some patients, a dose of 150mg may be acceptable.
Cosentyx was approved but contains labeling which informs patients that use of the medication may increase a patient’s risk for infection, and severe allergic reactions have been reported with the use of Cosentyx.
Novartis plans on launching Cosentyx in 5-8 weeks.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.